Cyclopharm Limited (CYC.AX)
AUD 1.07
(0.47%)
AUD 1.07
(0.47%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -9.22 Million AUD | -22.03% |
| 2022 | -7.27 Million AUD | -13.14% |
| 2021 | -6.43 Million AUD | 20.39% |
| 2020 | -8.08 Million AUD | -37.21% |
| 2019 | -5.89 Million AUD | -131.96% |
| 2018 | -2.53 Million AUD | -88.32% |
| 2017 | -1.34 Million AUD | -166.67% |
| 2016 | 2.02 Million AUD | -21.5% |
| 2015 | 2.57 Million AUD | -27.97% |
| 2014 | 3.57 Million AUD | 645.57% |
| 2013 | -655.74 Thousand AUD | -4.57% |
| 2012 | -627.07 Thousand AUD | 25.06% |
| 2011 | -836.73 Thousand AUD | -183.12% |
| 2010 | 1 Million AUD | -70.36% |
| 2009 | 3.39 Million AUD | 57.95% |
| 2008 | 2.15 Million AUD | 33.29% |
| 2007 | 1.61 Million AUD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -8.32 Million AUD | 0.0% |
| 2023 Q4 | -6.79 Million AUD | 0.0% |
| 2023 FY | -8.88 Million AUD | -22.03% |
| 2023 Q2 | -2.88 Million AUD | 0.0% |
| 2022 Q2 | -2.1 Million AUD | 0.0% |
| 2022 Q4 | -5.17 Million AUD | 0.0% |
| 2022 FY | -7.27 Million AUD | -13.14% |
| 2021 Q2 | -3.55 Million AUD | 0.0% |
| 2021 Q4 | -3.04 Million AUD | 0.0% |
| 2021 FY | -6.43 Million AUD | 20.39% |
| 2020 FY | -8.08 Million AUD | -37.21% |
| 2020 Q4 | -3.21 Million AUD | 0.0% |
| 2020 Q2 | -4.87 Million AUD | 0.0% |
| 2019 FY | -5.89 Million AUD | -131.96% |
| 2019 Q4 | -3.27 Million AUD | 0.0% |
| 2019 Q2 | -2.61 Million AUD | 0.0% |
| 2018 Q4 | 955.5 Thousand AUD | 0.0% |
| 2018 FY | -2.53 Million AUD | -88.32% |
| 2018 Q2 | -1.37 Million AUD | 0.0% |
| 2017 Q4 | 2.17 Million AUD | 0.0% |
| 2017 FY | -1.34 Million AUD | -166.67% |
| 2017 Q2 | -1.16 Million AUD | 0.0% |
| 2016 Q2 | 769.83 Thousand AUD | 0.0% |
| 2016 Q4 | 1.13 Million AUD | 0.0% |
| 2016 FY | 2.02 Million AUD | -21.5% |
| 2015 Q4 | 1.82 Million AUD | 0.0% |
| 2015 FY | 2.57 Million AUD | -27.97% |
| 2015 Q2 | 272.82 Thousand AUD | 0.0% |
| 2014 Q2 | 515.09 Thousand AUD | 0.0% |
| 2014 FY | 3.57 Million AUD | 645.57% |
| 2014 Q4 | 90.21 Thousand AUD | 0.0% |
| 2013 Q4 | 201.51 Thousand AUD | 0.0% |
| 2013 FY | -655.74 Thousand AUD | -4.57% |
| 2013 Q2 | -1.23 Million AUD | 47.9% |
| 2013 Q1 | -2.37 Million AUD | 0.0% |
| 2012 Q1 | -156.76 Thousand AUD | 0.0% |
| 2012 Q2 | -156.76 Thousand AUD | 0.0% |
| 2012 Q3 | -156.76 Thousand AUD | 0.0% |
| 2012 FY | -627.07 Thousand AUD | 25.06% |
| 2012 Q4 | -2.37 Million AUD | -1417.51% |
| 2011 Q3 | -209.18 Thousand AUD | 0.0% |
| 2011 FY | -836.73 Thousand AUD | -183.12% |
| 2011 Q4 | -156.76 Thousand AUD | 25.06% |
| 2011 Q1 | -209.18 Thousand AUD | 0.0% |
| 2011 Q2 | -209.18 Thousand AUD | 0.0% |
| 2010 Q1 | 251.67 Thousand AUD | 0.0% |
| 2010 FY | 1 Million AUD | -70.36% |
| 2010 Q4 | -209.18 Thousand AUD | -183.12% |
| 2010 Q3 | 251.67 Thousand AUD | 0.0% |
| 2010 Q2 | 251.67 Thousand AUD | 0.0% |
| 2009 Q3 | 676.25 Thousand AUD | 0.0% |
| 2009 Q4 | 251.67 Thousand AUD | -62.78% |
| 2009 FY | 3.39 Million AUD | 57.95% |
| 2009 Q1 | 676.25 Thousand AUD | 0.0% |
| 2009 Q2 | 676.25 Thousand AUD | 0.0% |
| 2008 Q3 | 537.6 Thousand AUD | 0.0% |
| 2008 Q2 | 537.6 Thousand AUD | 0.0% |
| 2008 Q1 | 537.6 Thousand AUD | 0.0% |
| 2008 FY | 2.15 Million AUD | 33.29% |
| 2008 Q4 | 676.25 Thousand AUD | 25.79% |
| 2007 Q4 | 537.6 Thousand AUD | 33.29% |
| 2007 Q1 | 403.33 Thousand AUD | 0.0% |
| 2007 Q3 | 403.33 Thousand AUD | 0.0% |
| 2007 Q2 | 403.33 Thousand AUD | 0.0% |
| 2007 FY | 1.61 Million AUD | 0.0% |
| 2006 Q4 | 403.33 Thousand AUD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| 4DMedical Limited | -27.96 Million AUD | 67.015% |
| Adherium Limited | -11.98 Million AUD | 23.034% |
| Aroa Biosurgery Limited | -9.78 Million AUD | 5.752% |
| Atomo Diagnostics Limited | -4.36 Million AUD | -111.503% |
| Anteris Technologies Ltd | -66.63 Million AUD | 86.156% |
| Control Bionics Limited | -5.92 Million AUD | -55.579% |
| CardieX Limited | -4.63 Million AUD | -99.077% |
| Compumedics Limited | -269 Thousand AUD | -3329.246% |
| Cochlear Limited | 521.5 Million AUD | 101.769% |
| CleanSpace Holdings Limited | -4.81 Million AUD | -91.623% |
| EMVision Medical Devices Ltd | -1.61 Million AUD | -471.396% |
| Nova Eye Medical Limited | -3.79 Million AUD | -142.946% |
| HeraMED Limited | -6.42 Million AUD | -43.508% |
| Imricor Medical Systems, Inc. | -17.57 Million AUD | 47.514% |
| ImpediMed Limited | -19.03 Million AUD | 51.541% |
| InhaleRx Limited | -1.38 Million AUD | -565.327% |
| LBT Innovations Limited | -4.74 Million AUD | -94.613% |
| Micro-X Limited | -13.02 Million AUD | 29.188% |
| Neurotech International Limited | -5.58 Million AUD | -65.175% |
| OncoSil Medical Limited | -11.98 Million AUD | 23.026% |
| PolyNovo Limited | 1.16 Million AUD | 893.179% |
| Respiri Limited | -7 Million AUD | -31.777% |
| SomnoMed Limited | -3.84 Million AUD | -140.145% |
| Universal Biosensors, Inc. | -16.68 Million AUD | 44.697% |
| Uscom Limited | -2.4 Million AUD | -283.666% |
| Visioneering Technologies, Inc. | -5.85 Million AUD | -57.575% |